Rosini Michela, Antonello Alessandra, Cavalli Andrea, Bolognesi Maria L, Minarini Anna, Marucci Gabriella, Poggesi Elena, Leonardi Amedeo, Melchiorre Carlo
Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.
J Med Chem. 2003 Nov 6;46(23):4895-903. doi: 10.1021/jm030952q.
In a search for structurally new alpha(1)-adrenoreceptor (alpha(1)-AR) antagonists, prazosin (1)-related compounds 2-11 were synthesized and their affinity profiles were assessed by functional experiments in isolated rat vas deferens (alpha(1A)), spleen (alpha(1B)), and aorta (alpha(1D)) and by binding assays in CHO cells expressing human cloned alpha(1)-AR subtypes. Transformation of the piperazinylquinazoline moiety of 1 into an aminomethyltetrahydroacridine system afforded compound 2, endowed with reduced affinity, in particular for the alpha(1A)-AR subtype. Then, to investigate the optimal features of the tricyclic moiety, the aliphatic ring of 2 was modified by synthesizing the lower and higher homologues 3 and 4. An analysis of the pharmacological profile, together with a molecular modeling study, indicated the tetrahydroacridine moiety as the most promising skeleton for alpha(1)-antagonism. Compounds 5-8, where the replacement of the furoyl group of 2 with a benzoyl moiety afforded the possibility to evaluate the effect of the substituent trifluoromethyl on receptor binding, resulted, except for 7, in a rather surprising selectivity toward alpha(1B)-AR, in particular vs the alpha(1A) subtype. Also the insertion of the 2,6-dimethoxyphenoxyethyl function of WB 4101 on the tetrahydroacridine skeleton of 2, and/or the replacement of the aromatic amino function with a hydroxy group, affording derivatives 9-11, resulted in alpha(1B)-AR selectivity also vs the alpha(1D) subtype. On the basis of these results, the tetrahydroacridine moiety emerged as a promising tool for the characterization of the alpha(1)-AR, owing to the receptor subtype selectivity achieved by an appropriate modification of the lateral substituents.
为了寻找结构新颖的α(1)-肾上腺素能受体(α(1)-AR)拮抗剂,合成了与哌唑嗪(1)相关的化合物2-11,并通过离体大鼠输精管(α(1A))、脾脏(α(1B))和主动脉(α(1D))的功能实验以及在表达人克隆α(1)-AR亚型的CHO细胞中的结合试验来评估它们的亲和力谱。将1的哌嗪基喹唑啉部分转化为氨基甲基四氢吖啶系统得到化合物2,其亲和力降低,特别是对α(1A)-AR亚型。然后,为了研究三环部分的最佳特征,通过合成较低和较高同系物3和4对2的脂肪环进行了修饰。药理学谱分析以及分子建模研究表明,四氢吖啶部分是α(1)-拮抗剂最有前景的骨架。化合物5-8中,用苯甲酰基部分取代2的呋喃甲酰基,使得能够评估取代基三氟甲基对受体结合的影响,结果除7外,对α(1B)-AR具有相当惊人的选择性,特别是相对于α(1A)亚型。同样,在2的四氢吖啶骨架上插入WB 4101的2,6-二甲氧基苯氧基乙基官能团和/或用羟基取代芳香氨基官能团,得到衍生物9-11,也导致相对于α(1D)亚型对α(1B)-AR具有选择性。基于这些结果,由于通过适当修饰侧链取代基实现了受体亚型选择性,四氢吖啶部分成为表征α(1)-AR的有前景的工具。